ATE162802T1 - Amyloid-peptide - Google Patents

Amyloid-peptide

Info

Publication number
ATE162802T1
ATE162802T1 AT88303803T AT88303803T ATE162802T1 AT E162802 T1 ATE162802 T1 AT E162802T1 AT 88303803 T AT88303803 T AT 88303803T AT 88303803 T AT88303803 T AT 88303803T AT E162802 T1 ATE162802 T1 AT E162802T1
Authority
AT
Austria
Prior art keywords
amylin
kcntat
found
peptides
synthetic
Prior art date
Application number
AT88303803T
Other languages
English (en)
Inventor
Garth James Smith Cooper
Anthony Charles Willis
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE162802T1 publication Critical patent/ATE162802T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT88303803T 1987-04-27 1988-04-27 Amyloid-peptide ATE162802T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878709871A GB8709871D0 (en) 1987-04-27 1987-04-27 Peptides

Publications (1)

Publication Number Publication Date
ATE162802T1 true ATE162802T1 (de) 1998-02-15

Family

ID=10616392

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88303803T ATE162802T1 (de) 1987-04-27 1988-04-27 Amyloid-peptide

Country Status (8)

Country Link
EP (1) EP0289287B1 (de)
JP (3) JP2766647B2 (de)
AT (1) ATE162802T1 (de)
CA (1) CA1341333C (de)
DE (1) DE3856121T2 (de)
ES (1) ES2114522T3 (de)
GB (1) GB8709871D0 (de)
GR (1) GR3026640T3 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454299B (sv) * 1986-10-08 1988-04-18 Westermark P Sats innehallande polypeptid som finns i pankreasoamyloid och/eller antikroppar riktade mot polypeptiden
GB8720115D0 (en) 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
EP0348490B1 (de) * 1988-01-11 1995-09-27 Amylin Pharmaceuticals, Inc. Behandlung von diabetes mellitus typ 2
US5405831A (en) * 1989-07-08 1995-04-11 Amylin Pharmaceuticals, Inc. Treatment of bone disorders
CA2020786A1 (en) * 1989-07-10 1991-01-11 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
EP0503827A1 (de) * 1991-03-15 1992-09-16 Pfizer Inc. Verwendung von Amylin und Calcitonin-Genverwandten Peptiden und Antagonisten davon
SG49239A1 (en) * 1991-05-24 1998-05-18 Amylin Pharmaceuticals Inc Amylin and possibly insulin containing composition for the treatment of aneroxia and related states
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
WO1993019774A1 (en) * 1992-04-03 1993-10-14 Amylin Pharmaceuticals, Inc. Amylin and possibly insulin containing composition for the treatment of anorexia and related states
BR9305525A (pt) * 1992-05-15 1995-03-01 Amylin Pharmaceuticals Inc Teste de anticorpos para amilina
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
AU7685894A (en) * 1993-09-07 1995-03-27 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
CN1147459C (zh) 1994-10-21 2004-04-28 Nps药物有限公司 钙受体活性化合物
CA2246431A1 (en) * 1996-01-19 1997-07-24 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
ATE430123T1 (de) 1996-05-01 2009-05-15 Nps Pharma Inc Inorganische am ionen-rezeptor aktive verbindungen
DE19725619A1 (de) * 1997-06-17 1998-12-24 Fraunhofer Ges Forschung Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie der Verwendung bei Alzheimer'schen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien
US6821954B2 (en) * 1997-09-18 2004-11-23 Auckland Uniservices Limited Compounds and uses thereof in treating bone disorders
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
US7217694B2 (en) * 2000-09-19 2007-05-15 The Governing Counsel Of The University Of Toronto Inhibitors of IAPP fibril formation and uses thereof
AU2003278929A1 (en) 2002-10-18 2004-05-13 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
EP2233497A3 (de) 2004-02-11 2011-01-12 Amylin Pharmaceuticals, Inc. Peptide der amylin Familie, Verfahren zu deren Herstellung und Verwendung
US20080004211A1 (en) * 2004-02-23 2008-01-03 Paul Fraser Inhibitors of Amyloid Fibril Formation and Uses Thereof
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
EP1774339A2 (de) * 2004-07-28 2007-04-18 F. Hoffmann-Roche AG Pankreatisches polypeptid als ziel/marker für beta-zellversagen
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
WO2006105527A2 (en) 2005-03-31 2006-10-05 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders
ES2397659T3 (es) 2006-03-15 2013-03-08 Novo Nordisk A/S Mezclas de amilina e insulina
CN102639559B (zh) * 2009-11-25 2015-04-29 诺沃—诺迪斯克有限公司 用于制备多肽的方法
CN103308670B (zh) * 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
HRP20181398T1 (hr) 2012-09-12 2018-10-19 Neurimmune Holding Ag Specifična antitijela za amiloid polipeptida humanih otočića (hiapp) i njegova upotreba
US9656017B2 (en) 2014-06-20 2017-05-23 Howard E. Greene Infusion delivery devices and methods
CN110467666A (zh) * 2019-09-17 2019-11-19 湖北强耀生物科技有限公司 一种新型胰岛淀粉样多肽的合成方法
TW202144387A (zh) * 2020-02-11 2021-12-01 美商聯合生物醫學公司 針對胰島澱粉樣多肽（iapp）的胜肽免疫原及其預防和治療與聚集iapp相關疾病的製劑
WO2025150507A1 (ja) * 2024-01-12 2025-07-17 学校法人東邦大学 インスリン・アミロイド化重合蛋白質、抗体、抗体産生ｂ細胞および医療用組成物
CN119930779A (zh) * 2025-02-10 2025-05-06 南京工业大学 采用淀粉样蛋白基序调节嵌合蛛丝蛋白亲疏水性的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE500044C2 (sv) * 1985-02-15 1994-03-28 Gambro Lundia Ab Peptidförening, antiserum framställt med användning av denna förening samt användning av föreningen
SE454299B (sv) * 1986-10-08 1988-04-18 Westermark P Sats innehallande polypeptid som finns i pankreasoamyloid och/eller antikroppar riktade mot polypeptiden
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus

Also Published As

Publication number Publication date
GR3026640T3 (en) 1998-07-31
ES2114522T3 (es) 1998-06-01
DE3856121T2 (de) 1998-07-23
JPH09133679A (ja) 1997-05-20
CA1341333C (en) 2002-01-22
HK1003033A1 (en) 1998-09-30
EP0289287B1 (de) 1998-01-28
EP0289287A2 (de) 1988-11-02
JPH10168099A (ja) 1998-06-23
JP2766647B2 (ja) 1998-06-18
GB8709871D0 (en) 1987-06-03
DE3856121D1 (de) 1998-03-05
EP0289287A3 (de) 1990-05-30
JPS6463594A (en) 1989-03-09

Similar Documents

Publication Publication Date Title
ATE162802T1 (de) Amyloid-peptide
EP0208491A3 (en) Hybrid polypeptides and process for their preparation
EG19101A (en) Process for preparing of expression of human proapolipoprotein A.1.
HUT46638A (en) Process for producing 1,1,1-trifluoro-2,2-dichloroethane in the presence of hydrogen fluoride catalyst
IL62553A0 (en) Vectors comprising dna sequences and methods for producing recombinant dna molecules and cloning vectors
HUT46356A (en) Process for producing the preprotein of apc polypeptide and the dna encoding it, as well as for the diagnostic utilization of the dna and the protein
DE3163867D1 (en) Novel substituted pyrazinyl-1,2,4-oxadiazol-5-ones, a process for preparing same and a pharmaceutical composition containing same
IL70414A (en) Polypeptide having human h2-relaxin activity,double-stranded dna fragments coding therefor,vectors containing the dna fragments and methods for preparing the polypeptide,dna fragments and vectors
HUT46061A (en) Dna sequences encoding hirudin-like protein and process for producing such proteins
HUT55801A (en) Process for producing anti-coagulative peptides marked with radioactivity
GB8720901D0 (en) Treating leather
GB8906511D0 (en) Process for producing semi-finished leather goods
DE69233005D1 (de) DNA kodierend für Propylendopeptidase und dessen Verwendung
ZA883115B (en) Treatment of diabetes
NO177570B (no) Fremgangsmåte ved fremstilling av peptider med fibronektinbindende egenskaper, mikroorganisme og DNA-sekvens som koder for peptider med fibronektinbindende egenskaper
HUT47136A (en) Process for producing cyclic peptides with anticoagulant effect
DE3260830D1 (en) Process for the manufacture of globin or blood cell protein and heme from hemoglobin
ATE78239T1 (de) Verfahren zur herstellung von zeolithen.
DE3851364D1 (de) Verfahren zur Herstellung von supraleitendem Material.
ZA902054B (en) Production and use of anthelmintic agents and protective immunogens
HUT53125A (en) Process for producing peptides with anticoagulant activity
PT73587A (en) Process for preparing novel peptides
EP0281089A3 (en) Process for the preparation of factor viii:c deficient plasma, and deficient plasma obtained therwith
GB2220215B (en) Process for treating leather
DE3851214D1 (de) Verfahren zur Herstellung von flachen Vorrichtungen zum Pumpen von Sauerstoff.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time